October 02, 2014 12:35 PM ET

Pharmaceuticals

Company Overview of Arbor Pharmaceuticals, LLC

Company Overview

Arbor Pharmaceuticals, LLC operates as a specialty pharmaceutical company that develops, manufactures, and commercializes prescription products for cardiovascular and pediatric disorders. Its products include Nitrolingual pumpspray for the acute relief of an attack or the prophylaxis of angina pectoris due to coronary artery disease; EDARBI, an angiotensin II receptor blocker for the treatment of hypertension to lower blood pressure; EDARBYCLOR, an angiotensin II receptor blocker and a thiazide-like diuretic drug that is used for the treatment of hypertension to lower blood pressure; BiDil, a prescription drug for heart disease; GLIADEL Wafer, a drug that is used for the treatment of maligna...

Six Concourse Parkway

Suite 1800

Atlanta, GA 30328

United States

Founded in 2006

Phone:

678-334-2420

Fax:

678-334-2433

Key Executives for Arbor Pharmaceuticals, LLC

Chief Executive Officer
Age: 62
Founder and Vice President of Commercial Development
Vice President of Finance & Accounting
Chief Compliance Officer
Age: 45
Vice President of Business Development
Compensation as of Fiscal Year 2014.

Arbor Pharmaceuticals, LLC Key Developments

Arbor Pharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Arbor Pharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Arbor Pharmaceuticals Announces FDA Acceptance for Filing of its Second NDA

Arbor Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its second New Drug Application (NDA). The NDA was originally filed with the FDA on December 23, 2013 and officially accepted for filing on February 23, 2014. Arbor's first NDA, Nymalize(R) (nimodipine) oral solution, was approved in May of last year. Arbor has a total of seven other branded projects in development consisting of both 505(b)(1) and 505(b)(2) type filings. One of these projects is in phase three clinical development and three are currently in phase two studies. In addition to these NDAs, Arbor has ten Abbreviated New Drug Applications (ANDAs) filed with the FDA through its Wilshire generic division or one of partner companies. Wilshire also has an additional 25 ANDAs in various stages of development. Arbor Pharmaceuticals has been assigned a Prescription Drug User Fee Approval date (PDUFA) of October 23, 2014 for this NDA.

Arbor Pharmaceuticals, LLC Presents at Fourth-Annual Healthcare, Consumer, and Private Equity Conference, Mar-13-2014

Arbor Pharmaceuticals, LLC Presents at Fourth-Annual Healthcare, Consumer, and Private Equity Conference, Mar-13-2014 . Venue: Charlotte Country Club. Speakers: Edward Schutter, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Methapharm Inc. United States
The Tylenol Company United States
BlueKiwi Inc. United States
CeNeRx BioPharma, Inc. United States
Upsher-Smith Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Arbor Pharmaceuticals, LLC, please visit www.arborpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.